Read by QxMD icon Read

Macular oedema

Takayo Watanabe, Hiroshi Keino, Kyoko Nakayama, Wakako Taki, Nariaki Echizen, Annabelle A Okada
AIM: To describe clinical features and outcomes of new-onset anterior uveitis associated with poorly controlled or undiagnosed diabetes mellitus. METHODS: Retrospective analysis of 25 eyes of 18 patients (14 men, 4 women; mean age 44 years) who presented between December 2001 and October 2016 to the Kyorin Eye Center. RESULTS: Ocular findings at presentation included posterior synechiae (15 eyes, 60%), anterior chamber fibrin (13 eyes, 52%), keratic precipitates (10 eyes, 40%), Descemet membrane folds (7 eyes, 28%) and hypopyon (3 eyes, 12%)...
March 21, 2018: British Journal of Ophthalmology
Ahmed Al-Janabi, Sue Lightman, Oren Tomkins-Netzer
Statins are known for their blood cholesterol-lowering effect and are widely used in patients with cardiovascular and metabolic diseases. Research over the past three decades shows that statins have diverse effects on different pathophysiological pathways involved in angiogenesis, inflammation, apoptosis, and anti-oxidation, leading to new therapeutic options. Recently, statins have attracted considerable attention for their immunomodulatory effect. Since immune reactivity has been implicated in a number of retinal diseases, such as uveitis, age-related macular degeneration (AMD) and diabetic retinopathy, there is now a growing body of evidence supporting the beneficial effects of statins in these retinopathies...
March 20, 2018: Eye
Taiji Hasegawa, Sakura Murakawa, Ichiro Maruko, Akiko Kogure-Katakura, Tomohiro Iida
AIM: To determine whether there is a significant correlation between the reduction in macular vessel density and the recurrence of macular oedema in eyes with branch retinal vein occlusion (BRVO). METHODS: We reviewed the medical records of 27 eyes with macular oedema associated with BRVO. All eyes had received pro re nata intravitreal ranibizumab (IVR) injection. A reinjection of ranibizumab was performed when the central foveal thickness was ≥300 µm. At 12 months, patients without additional IVR for the last 4 months were placed in the resolved group, otherwise they were placed in the recurrence group...
March 15, 2018: British Journal of Ophthalmology
Ramachandran Rajalakshmi, Radhakrishnan Subashini, Ranjit Mohan Anjana, Viswanathan Mohan
OBJECTIVES: To assess the role of artificial intelligence (AI)-based automated software for detection of diabetic retinopathy (DR) and sight-threatening DR (STDR) by fundus photography taken using a smartphone-based device and validate it against ophthalmologist's grading. METHODS: Three hundred and one patients with type 2 diabetes underwent retinal photography with Remidio 'Fundus on phone' (FOP), a smartphone-based device, at a tertiary care diabetes centre in India...
March 9, 2018: Eye
Tien Yin Wong
No abstract text is available yet for this article.
March 5, 2018: Lancet Diabetes & Endocrinology
Sobha Sivaprasad, Joana C Vasconcelos, A Toby Prevost, Helen Holmes, Philip Hykin, Sheena George, Caroline Murphy, Joanna Kelly, Geoffrey B Arden
BACKGROUND: We aimed to assess 24-month outcomes of wearing an organic light-emitting sleep mask as an intervention to treat and prevent progression of non-central diabetic macular oedema. METHODS: CLEOPATRA was a phase 3, single-blind, parallel-group, randomised controlled trial undertaken at 15 ophthalmic centres in the UK. Adults with non-centre-involving diabetic macular oedema were randomly assigned (1:1) to wearing either a light mask during sleep (Noctura 400 Sleep Mask, PolyPhotonix Medical, Sedgefield, UK) or a sham (non-light) mask, for 24 months...
March 5, 2018: Lancet Diabetes & Endocrinology
Dominika Podkowinski, Ana-Maria Philip, Wolf-Dieter Vogl, Jutta Gamper, Hrvoje Bogunovic, Bianca S Gerendas, Bilal Haj Najeeb, Sebastian M Waldstein, Ursula Schmidt-Erfurth
BACKGROUND/AIMS: To characterise neuroretinal atrophy in retinal vein occlusion (RVO). METHODS: We included patients with central/branch RVO (CRVO=196, BRVO=107) who received ranibizumab according to a standardised protocol for 6 months. Retinal atrophy was defined as the presence of an area of retinal thickness (RT) <260 µm outside the foveal centre. Moreover, the thickness of three distinct retinal layer compartments was computed as follows: (1) retinal nerve fibre layer to ganglion cell layer, (2) inner plexiform layer (IPL) to outer nuclear layer (ONL) and (3) inner segment/outer segment junction to retinal pigment epithelium...
March 6, 2018: British Journal of Ophthalmology
Clare F McCloskey, Ann-Marie Mongan, Shivona Chetty, Darren M J McAteer, Shauna M Quinn
INTRODUCTION: To determine visual and anatomical outcomes of diabetic macular oedema (DMO) patients in a tertiary centre following conversion to aflibercept having been refractory to previous treatment with bevacizumab/ranibizumab. METHODS: A retrospective case series of patients with a diagnosis of DMO undergoing aflibercept intravitreal therapy for at least 6 months who had previous treatment with three consecutive bevacizumab/ranibizumab injections pre-switch...
March 5, 2018: Ophthalmology and Therapy
Rossiana I Bojinova, Daniel F Schorderet, Christophe Valmaggia, Cengiz Türksever, Andreas Schoetzau, Margarita G Todorova
PURPOSE: Primary objective-to investigate the effect of retinal vessel oxygen saturation (SO2 ) on macular oedema (ME) in retinitis pigmentosa (RP) patients. Secondary objective-to link the presence of ME to metabolic (oxygen saturation of retinal vessels, SO2 ), functional (multifocal electroretinography, mfERG) and structural (Spectral Domain Optical Coherent Tomography, SD-OCT) alterations in RP. DESIGN: Prospective, cross-sectional, non-interventional study...
March 6, 2018: Eye
Jingli Guo, WenYi Tang, Xiaofeng Ye, Haixiang Wu, Gezhi Xu, Wei Liu, Yongjin Zhang
BACKGROUND: To evaluate the structural changes associated with visual acuity (VA) in patients with idiopathic macular telangiectasia (MT) type 1 using multimodal imaging modalities. METHODS: A retrospective study of 14 patients with MT type 1 and of 10 eyes from 10 healthy individuals as age-matched controls was conducted. The medical records of patients who had undergone colour fundus photography, spectral domain optical coherence tomography (OCT), fluorescein angiography and OCT angiography were reviewed...
March 5, 2018: BMC Ophthalmology
Mario Fruschelli, Marco Capozzoli, Maria Chiara Gelmi, Gianni Masi, Pasquale Annunziata
PURPOSE: Fingolimod is the first oral drug approved for treatment of relapsing-remitting multiple sclerosis (RR-MS), and it has potential macular side effects. Despite the qualitative evidence of macular oedema under treatment, longitudinal quantitative assessment is lacking. To address this issue, we measured macular volume and central foveal thickness in a cohort of MS patients on fingolimod over 12 months of treatment. METHODS: Central foveal thickness (CFT) and total macular volume (TMV) were longitudinally recorded with spectral-domain optical coherence tomography in a cohort of 23 RR-MS patients treated with fingolimod at baseline, 3, 6 and 12 months...
March 2, 2018: International Ophthalmology
William Fusi-Rubiano, Chandoshi Mukherjee, Mark Lane, Marie D Tsaloumas, Nicholas Glover, Andrej Kidess, Alastair K Denniston, Helen E Palmer, Avinash Manna, Rupal Morjaria
BACKGROUND: To compare visual function and structural improvements in pseudophakic eyes with diabetic macular oedema (DMO) treated with the 0.19mg Fluocinolone Acetonide (FAc) intravitreal implant (IluvienTM ) in a 'real world' setting. METHODS: A single centre retrospective evaluation of patients with DMO unresponsive to conventional treatment treated with the FAc implant according to UK guidelines. Primary efficacy endpoint was best corrected visual acuity (BCVA); secondary endpoints included optical coherence tomography evaluations of the macula (a) central retinal and (b) peak macular thickness collected at annual time points...
February 27, 2018: BMC Ophthalmology
Sandra Rezar-Dreindl, Katharina Eibenberger, Wolf Buehl, Günther Weigert, Michael Georgopoulos, Ursula Schmidt-Erfurth, Stefan Sacu
BACKGROUND: To evaluate the change in peripheral perfusion status in patients with retinal vein occlusion (RVO) during dexamethasone treatment. METHODS: Thirty-five eyes of patients with macular oedema due to either branch or central retinal vein occlusion were included. At baseline, patients were treated with an intravitreal dexamethasone implant (Ozurdex® ) and followed until month 6. Wide-field angiographies were classified as ischaemic and nonischaemic. Peripheral nonperfusion (PNP) was determined manually by calculating the percentage of nonperfusion area in relation to the total visible retina (ischaemic index)...
February 27, 2018: Acta Ophthalmologica
Belén Atienza-Mateo, Vanesa Calvo-Río, Emma Beltrán, Lucía Martínez-Costa, Elia Valls-Pascual, Marisa Hernández-Garfella, Antonio Atanes, Miguel Cordero-Coma, Joan Miquel Nolla, Carmen Carrasco-Cubero, Javier Loricera, María C González-Vela, Nuria Vegas-Revenga, Carlos Fernández-Díaz, Rosalía Demetrio-Pablo, Lucía C Domínguez-Casas, José Luis Martín-Varillas, Natalia Palmou-Fontana, José L Hernández, Miguel Á González-Gay, Ricardo Blanco
Objective: To assess the efficacy of tocilizumab (TCZ) in refractory uveitis of Behçet's disease (BD). Methods: Multicentre study of patients with BD-associated uveitis. Patients were refractory to conventional and biologic immunosuppressive drugs. The main outcome measures were intraocular inflammation, macular thickness, visual acuity and corticosteroid-sparing effects. Results: We studied 11 patients (7 men) (20 affected eyes); median age 35 years...
February 19, 2018: Rheumatology
Riccardo Sacconi, Eleonora Corbelli, Adriano Carnevali, Stefano Mercuri, Alessandro Rabiolo, Lea Querques, Giorgio Marchini, Francesco Bandello, Giuseppe Querques
AIMS: To describe optical coherence tomography angiography (OCT-A) abnormalities of patients with pseudophakic cystoid macular oedema (PCMO) before and after pharmacological resolution, compared with diabetic macular oedema (DMO) and normal eyes. METHODS: In this retrospective, observational study, 44 eyes (30 patients) were included: 15 eyes (15 patients) affected by PCMO; 14 healthy fellow eyes used as negative control group; 15 eyes (15 age-matched and sex-matched patients) with DMO used as positive control group...
February 20, 2018: British Journal of Ophthalmology
I Temblador-Barba, E M Delgado-Alonso, M Toribio-García, L Martínez-Campillo, I Molina-Leyva, M Martínez-Jiménez
CASE REPORT: Here we report a 19-year-old female patient who presented a vasoproliferative tumour. It caused complications, such as epiretinal membrane, macular oedema, vitreous haemorrhage, and exudative retinal detachment. The patient was treated with 3 injections of intravitreal bevacizumab, an intravitreal dexamethasone implant, tocilizumab, and double freeze-thaw cryotherapy. DISCUSSION: Therapeutic options are: observation, if it is small, if it is a peripheral lesion, and if there seems to be no threat to vision...
February 16, 2018: Archivos de la Sociedad Española de Oftalmología
L Brazionis, A Jenkins, A Keech, C Ryan, A Brown, J Boffa, S Bursell
AIM: To determine diabetic retinopathy prevalence and severity among remote Indigenous Australians. METHODS: A cross-sectional diabetic retinopathy screening study of Indigenous adults with Type 2 diabetes was conducted by locally trained non-ophthalmic retinal imagers in a remote Aboriginal community-controlled primary healthcare clinic in Central Australia and certified non-ophthalmic graders in a retinal grading centre in Melbourne, Australia. The main outcome measure was prevalence of any diabetic retinopathy and sight-threatening diabetic retinopathy...
February 6, 2018: Diabetic Medicine: a Journal of the British Diabetic Association
Katja Hatz, Andreas Ebneter, Cengiz Tuerksever, Christian Pruente, Martin Zinkernagel
PURPOSE: To investigate dexamethasone intravitreal implant 0.7 mg (DEX implant) for the treatment of diabetic macular oedema (DME) refractory to anti-vascular endothelial growth factor (anti-VEGF) therapy and evaluate predictive factors. METHODS: Two-centre retrospective interventional case series, including 40 eyes of 31 patients treated with DEX implant for at least 2 consecutive cycles. RESULTS: Mean ± SD intervals from implantation to recurrence in the first (4...
February 2, 2018: Ophthalmologica. Journal International D'ophtalmologie
Neha Goel
OBJECTIVE: To describe outcomes of combined pars plana vitrectomy (PPV) and trans-scleral 4-point suture fixation of a foldable Akreos AO60 intraocular lens (IOL) in eyes with subluxated or dislocated lens or IOL. METHODS: Retrospective case series of 20 eyes of 18 patients who underwent this procedure with a minimum follow-up of 3 months. Outcome measures included final best-corrected Snellen visual acuity (BCVA), spherical equivalent (SE) and intraoperative and postoperative complications...
February 5, 2018: Eye
J A Reche-Sainz, O Gutiérrez-Montero
CLINICAL CASE: A 27-year-old male with sudden visual loss of OD. He had a past history of heavy smoking, as well as a chronic ischaemia of his left lower limb of one-year onset. This led to a diagnosis of Buerger's disease, which is an inflammatory thrombotic disorder that affects small and medium vessels. The visual acuity (VA) of OD was 0.9, and in the funduscopy a very congestive papilla was observed, along with venous tortuosity, scattered retinal haemorrhages, but without macular oedema...
February 1, 2018: Archivos de la Sociedad Española de Oftalmología
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"